Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS)

NSE:AKUMS Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Operating Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	2,552	3,382	-40.35	948.55	-2,525
Depreciation & Amortization	1,525	1,509	1,235	1,112	923.9
Other Amortization	21	25.16	21.35	16.34	22.89
Loss (Gain) From Sale of Assets	0.55	1.12	11.78	1.75	20.66
Asset Writedown & Restructuring Costs	-0.63	-38.27	-1.38	675.14	119.22
Loss (Gain) on Equity Investments	-	-	-	2.03	-2.03
Provision & Write-off of Bad Debts	294.21	294.11	134.01	43.14	188.62
Other Operating Activities	198.4	-817.4	3,123	-689.05	5,086
Change in Accounts Receivable	-522.57	342.14	-32.32	349.11	-3,718
Change in Inventory	-747.82	-505.71	837.29	-73.47	-2,926
Change in Accounts Payable	-297.43	1,153	-291.96	-183.69	2,505
Change in Other Net Operating Assets	8,790	-692.95	-14.34	-435.29	623
Operating Cash Flow	11,812	4,652	4,983	1,766	318.54
Operating Cash Flow Growth	153.91%	-6.64%	182.09%	454.50%	-75.61%

Investing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-2,305	-2,723	-3,114	-3,288	-2,576
Sale of Property, Plant & Equipment	77.48	85.47	249.93	421.47	19.24
Cash Acquisitions	-0.25	-	-	-16.2	-110.02
Investment in Securities	-7,461	-3,091	-634.75	-449.53	247.07
Other Investing Activities	386.57	249.86	121.02	303.9	46.31
Investing Cash Flow	-9,303	-5,478	-3,304	-3,047	-2,348

Financing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Short-Term Debt Issued	592.99	-	-	485.79	2,524
Long-Term Debt Issued	-	-	102.94	1,402	200.19
Total Debt Issued	592.99	-	102.94	1,887	2,724
Short-Term Debt Repaid	-	-3,540	-236.3	-	-
Long-Term Debt Repaid	-93.7	-1,760	-442.72	-237.56	-274.92
Total Debt Repaid	-93.7	-5,301	-679.02	-237.56	-274.92
Net Debt Issued (Repaid)	499.29	-5,301	-576.08	1,650	2,450
Issuance of Common Stock	-	6,374	-	-	-
Other Financing Activities	-160.49	-345.08	-504.13	-404.43	-89.1
Financing Cash Flow	338.8	727.88	-1,080	1,245	2,360

Net Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Miscellaneous Cash Flow Adjustments	-	-	-3.81	-	-
Net Cash Flow	2,848	-98.59	594.42	-35.31	330.72

Free Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	9,507	1,929	1,869	-1,522	-2,257
Free Cash Flow Growth	392.87%	3.23%	-	-	-
Free Cash Flow Margin	21.80%	4.68%	4.47%	-4.16%	-6.14%
Free Cash Flow Per Share	62.09	12.89	13.06	-10.64	-15.78
Levered Free Cash Flow	932.99	354.7	760.05	-1,950	-2,550
Unlevered Free Cash Flow	1,487	544.75	1,074	-1,662	-2,447

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	160.49	345.08	504.13	404.43	89.1
Cash Income Tax Paid	873.68	812.35	624.2	970.63	548.18
Change in Working Capital	7,222	296.18	498.67	-343.34	-3,516

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 19, 2026

Data Sources Report a data error